Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25% import duty on Indian goods. Investors were also monitoring the ongoing earnings season. The Nifty settled below the 24,600 level after hitting the days high of 24,784.15 in mid-morning trade.

Barring the Nifty FMCG index, all the other sectoral indices on the NSE ended in red.

As per provisional closing data, the barometer index, the S&P BSE Sensex declined 585.67 points or 0.72% to 80,599.91. The Nifty 50 index lost 203 points or 0.82% to 24,565.35.

The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index slipped 1.37% and the S&P BSE Small-Cap index declined 1.59%.

The market breadth was weak. On the BSE, 1,307 shares rose and 2,711 shares fell. A total of 151 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, rallied 3.74% to 11.98

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’